+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Preclinical Imaging (In-VIVO) - Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4805695
The global market for Preclinical Imaging (In-VIVO) was estimated at US$1.0 Billion in 2023 and is projected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Preclinical Imaging (In-VIVO): Advancing Biomedical Research

Preclinical imaging (in-vivo) refers to the use of advanced imaging techniques to visualize and study biological processes in live animal models, primarily for biomedical research purposes. This imaging is conducted before clinical trials in humans, helping researchers understand disease mechanisms, evaluate the efficacy of new drugs, and monitor treatment effects in real-time. Common imaging modalities used in preclinical research include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging techniques such as bioluminescence and fluorescence imaging. The importance of preclinical imaging lies in its ability to provide detailed insights into the biological processes underlying health and disease, enabling researchers to make informed decisions in drug development and other areas of biomedical research. By allowing non-invasive monitoring of disease progression and treatment response, preclinical imaging plays a crucial role in the advancement of medical science.

How Are Technological Advancements Enhancing Preclinical Imaging (In-VIVO)?

Technological advancements have significantly improved the capabilities of preclinical imaging, enhancing both the resolution and functionality of imaging modalities. Innovations in imaging hardware, such as higher-field MRI magnets and more sensitive PET detectors, have increased the spatial and temporal resolution of images, allowing for more detailed visualization of biological processes. The development of multimodal imaging systems, which combine two or more imaging techniques (e.g., PET/CT or MRI/PET), has enabled researchers to simultaneously capture complementary data, providing a more comprehensive understanding of disease mechanisms and treatment effects. Advances in molecular imaging agents, including targeted contrast agents and radiotracers, have improved the specificity of imaging, allowing for the visualization of specific molecular pathways and cellular processes. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into image analysis has enhanced the ability to process and interpret complex imaging data, facilitating more accurate and efficient research outcomes. These technological improvements have expanded the applications and impact of preclinical imaging, making it an indispensable tool in biomedical research.

What Are the Key Applications and Benefits of Preclinical Imaging (In-VIVO)?

Preclinical imaging (in-vivo) is used in various research areas, offering numerous benefits that advance the understanding of disease and the development of new treatments. In oncology research, preclinical imaging allows for the non-invasive tracking of tumor growth and metastasis, helping researchers evaluate the effectiveness of cancer therapies in real-time. In neuroscience, imaging techniques such as MRI and PET are used to study brain structure and function, providing insights into neurological disorders such as Alzheimer's disease and Parkinson's disease. Cardiovascular research benefits from preclinical imaging through the visualization of heart and blood vessel function, aiding in the study of heart disease and the development of new cardiovascular drugs. Additionally, preclinical imaging is used in pharmacokinetics and pharmacodynamics studies to monitor the distribution and action of drugs within the body. The primary benefits of preclinical imaging include the ability to conduct non-invasive, real-time monitoring of biological processes, the reduction of animal use through longitudinal studies, and the generation of high-resolution data that can inform clinical research. These advantages make preclinical imaging a critical component of modern biomedical research.

What Factors Are Driving the Growth in the Preclinical Imaging (In-VIVO) Market?

The growth in the preclinical imaging (in-vivo) market is driven by several factors. The increasing demand for more precise and non-invasive methods to study disease mechanisms and evaluate drug efficacy is a significant driver, as preclinical imaging provides critical insights that inform clinical research and drug development. Technological advancements that enhance the resolution, sensitivity, and functionality of imaging modalities are also propelling market growth. The expansion of the pharmaceutical and biotechnology industries, particularly in the area of personalized medicine, is contributing to the increased demand for preclinical imaging tools. Additionally, the growing emphasis on reducing animal use in research, coupled with the ability of preclinical imaging to enable longitudinal studies in the same animals, is further boosting market adoption. The integration of advanced data analysis techniques, including AI and machine learning, is enhancing the utility of preclinical imaging, driving its continued growth. These factors, combined with the ongoing innovation in imaging technologies, are driving the sustained growth of the preclinical imaging (in-vivo) market.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Preclinical Imaging Modalities segment, which is expected to reach US$900.1 Million by 2030 with a CAGR of a 5.2%. The Preclinical Imaging Reagents segment is also set to grow at 4.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $278.7 Million in 2023, and China, forecasted to grow at an impressive 4.6% CAGR to reach $225.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Preclinical Imaging (In-VIVO) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Preclinical Imaging (In-VIVO) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Preclinical Imaging (In-VIVO) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Aspect Imaging Ltd., Bruker Corp., Idex Health & Science LLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 38 Featured):

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens A.G.
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Preclinical Imaging (In-VIVO) - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Technological Advancements in Imaging Modalities Propel Market Growth
  • Rising Prevalence of Chronic Diseases Expands Addressable Market Opportunity
  • Growing Adoption of Multimodal Imaging Solutions Throws the Spotlight on Innovation
  • Focus on Drug Discovery and Development Accelerates Market Dynamics
  • Expansion of Contract Research Organizations (CROs) Boosts Market Prospects
  • Increasing Use of Imaging in Oncology Research Propels Market Expansion
  • Adoption of AI and Machine Learning in Image Analysis Drives Market Dynamics
  • Focus on Non-invasive Imaging Techniques Sustains Market Growth
  • Growing Investments in Preclinical Studies for Rare Diseases Expands Market Reach
  • Focus on Improving Image Resolution and Accuracy Enhances Market Opportunities
  • Regulatory Support for Preclinical Research Activities Propels Market Dynamics
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Preclinical imaging modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Preclinical imaging reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Preclinical Imaging (In-VIVO) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: USA 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: Canada 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
JAPAN
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: Japan 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
CHINA
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: China 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
EUROPE
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
FRANCE
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: France 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
GERMANY
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Germany 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Italy 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: UK 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Rest of Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Asia-Pacific 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens A.G.
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

Table Information